Prospective Study of the SoundBite™ Crossing System in Complex Peripheral CTOs (NCT03933657) | Clinical Trial Compass
WithdrawnNot Applicable
Prospective Study of the SoundBite™ Crossing System in Complex Peripheral CTOs
Stopped: Replaced by CaTO-PAD/BTK Study
Austria, Germany0Started 2022-12-30
Plain-language summary
This study aims at assessing additional performance characteristics of the SoundBite™ Crossing System with regards to the luminal passage of complex Chronic Total Occlusions (CTO) by evaluating clinically relevant efficacy, safety, cost benefit and treatment pathway endpoints.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
General Inclusion Criteria
* Has symptomatic non-acute limb ischemia, requiring treatment of an infrainguinal artery
* Has Rutherford Clinical Category of 2-6
* is able and willing to provide written informed consent prior to study procedure
Angiographic Inclusion Criteria
* 100% stenosis by a visual estimate of angiography at the time of the procedure
* target CTO has moderate to severe calcification
* Has at least one of the following: severe calcification, flush occlusion, femoropopliteal CTOs with reconstitution below Popliteal 2-3, side directing collateral at the proximal cap, long (≥ 5cm) occlusions, below the knee (BTK) occlusion.
* Has evidence of a clinically significant CTO located in a peripheral vessel below the infrainguinal ligament confirmed by angiography at time of the procedure.
Exclusion Criteria:
General Exclusion Criteria
* Insufficient kidney function or renal failure
* Subject has positive pregnancy test result
* Participation in any study of a study device, medication, biologic, or other agent during study or within 30 days prior to enrollment that is either a cardiovascular study or could, in the judgment of the investigator, affect the results of this study
* Subject in whom antiplatelet, anticoagulant therapy is contraindicated
* Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000/ml or known coagulopathy
* Known, untreated allergy to contrast agents or medication…
What they're measuring
1
Successful CTO Crossing assessed by angiographic imaging